特宝生物益佩生®纳入医保 以差异化创新兑现临床价值

Core Viewpoint - The successful inclusion of Teva Biopharma's long-acting growth hormone, Yipei Growth Hormone Injection (brand name: Yipei®), into the medical insurance directory signifies a major milestone for the company, highlighting the importance of differentiated innovative drugs with significant clinical advantages and higher safety in gaining recognition and support [1][2] Group 1 - The inclusion of Yipei® in the medical insurance directory marks national market access for the product, validating the company's core business proposition [1] - Yipei®'s successful entry is attributed to its strong "quality hard power," particularly breakthroughs in molecular design and safety upgrades, creating a difficult-to-replicate competitive advantage [1] - Teva Biopharma has focused on high-barrier biotechnological advancements, translating them into clinical benefits that address user pain points [1] Group 2 - The "Zhu Feng Project" supported by Teva Biopharma has provided clinical cure hope for numerous hepatitis B patients, while Yipei® aims to ensure that more children with growth disorders can access and safely use long-acting growth hormones [2] - The inclusion of Yipei® in the medical insurance directory is expected to significantly enhance drug accessibility and reduce the financial burden on patients' families, allowing high-quality innovative drugs to reach ordinary households [2] - By adhering to high standards and preservative-free production processes, the company ensures that increased accessibility does not compromise the safety and efficacy of its products [2]